News
Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions
SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials. These market-driven value propositions represent the latest...
Clinical Trials
CyanVac Selects Exothera for the Development and GMP Mfg anufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and...
CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a proprietary parainfluenza virus 5 (PIV5) vector.
Exothera...
News
Stelis concludes US$ 195m Series B and Series C fund raise
Stelis Biopharma (Stelis) announced that it has successfully concluded its Series B and Series C fund raise for a cumulative amount of US$ 195m. Post money valuation for Stelis will be pegged at ~US$ 350m, underpinning the significant growth...
News
Peli BioThermal Broadens Portfolio of Dry Ice Shippers
Peli BioThermal, the global name in temperature controlled packaging, announces expanded dry ice shipper options to support exponential growth in cell and gene therapy shipments worldwide, as well as continued need to transport pandemic payloads. Available parcel sizes range...
News
Roche’s antibody cocktail lowers hospitalisation by 70% in Covid-19 patients
Roche has reported that the Phase III REGN-COV 2067 trial of investigational antibody cocktail of casirivimab and imdevimab met its primary endpoint of reducing the risk of hospitalisation or death in treating high-risk, non-hospitalised Covid-19 patients, by 70%.
Regeneron scientists...
Clinical Trials
Phase 3 Trial Shows REGEN-COV antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing...
Clinical Trials
BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging
BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, announced that it has commenced a Phase 2 clinical trial of BGE-175, a potent oral inhibitor of prostaglandin D2(PGD2) DP1 signaling with a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read